Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02752126
Previous Study | Return to List | Next Study

A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus (PROACTIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02752126
Recruitment Status : Completed
First Posted : April 26, 2016
Last Update Posted : September 9, 2020
Sponsor:
Information provided by (Responsible Party):
Alexander Louie, Lawson Health Research Institute

Brief Summary:
A randomized phase II study of palliative radiation of advanced central lung tumors with intentional avoidance of the esophagus. Patients will be randomized between standard of care palliative thoracic radiation and esophageal-sparing intensity-modulated radiation therapy (ES-IMRT) in a 1:1 ratio. Radiotherapy will be administered as soon as possible following randomization and subjects will be followed for 1 year after completion of their radiation therapy. The primary endpoint is esophageal quality of life as measured by the Esophageal Cancer Subscore (ECS) of the Functional Assessment of Cancer Therapy-Esophagus (FACT-E).

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Radiation: Conventional radiotherapy Radiation: Esophageal-Sparing Intensity-Modulated Radiotherapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus
Study Start Date : June 2016
Actual Primary Completion Date : August 1, 2020
Actual Study Completion Date : September 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Standard Palliative Radiation
Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.
Radiation: Conventional radiotherapy
Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.

Experimental: Esophageal Sparing IMRT
Patients on the experimental arm will receive esophageal-sparing intensity-modulated radiotherapy, with the same dose(s) as in the standard arm.
Radiation: Esophageal-Sparing Intensity-Modulated Radiotherapy
Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.




Primary Outcome Measures :
  1. Esophageal Quality of Life [ Time Frame: 2 weeks after completion of radiotherapy ]
    Esophageal quality of life will be measured by the ECS of the FACT-E, measured at 2 weeks.


Secondary Outcome Measures :
  1. Survival [ Time Frame: 6 months after completion of radiotherapy ]
    Survival

  2. Toxicity Rate Differences [ Time Frame: 6 months after completion of radiotherapy ]
    Differences in rates of grade 2 or higher toxicity between groups will be tested using the Fisher's Exact test.

  3. Progression-Free Survival [ Time Frame: 6 months after completion of radiotherapy ]
    Differences in local/regional progression-free survival will be tested using the stratified log-rank test

  4. Further Systemic Therapy [ Time Frame: 6 months after completion of radiotherapy ]
    Differences in number of cycles of further systemic therapy will be tested using the student's t-test

  5. Cost-Effectiveness/Utility Analysis [ Time Frame: 6 months after completion of radiotherapy ]
    European Quality of Life-5 Dimensions (EQ-5D) measurements will be converted into utilities to inform cost-effectiveness/utility analysis.

  6. Dosimetry Comparison - Gross Tumor Volume (GTV) [ Time Frame: 6 months after completion of radiotherapy ]
    Dosimetric comparison of GTV will be compared using the student's t-test.

  7. Dosimetry Comparison - Planning Target Volume (PTV) [ Time Frame: 6 months after completion of radiotherapy ]
    Dosimetric comparison of PTV will be compared using the student's t-test.

  8. Dosimetry Comparison - Pulmonary Metrics [ Time Frame: 6 months after completion of radiotherapy ]
    Dosimetric comparison of standard pulmonary metrics will be compared using the student's t-test.

  9. Dosimetry Comparison - Esophageal Metrics [ Time Frame: 6 months after completion of radiotherapy ]
    Dosimetric comparison of standard esophageal metrics will be compared using the student's t-test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • American Joint Committee on Cancer (AJCC) 7th edition stage IV NSCLC or stage III not eligible for curative intent treatment
  • Intended to receive palliative radiotherapy to the thorax, to a dose of 30Gy in 10 fractions or 20Gy in 5 fractions. In either treatment arm at least 5cm of the esophagus should be in the intended treatment field.
  • Willingness and ability to provide informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-3
  • Age 18 years or older
  • Prior or planned systemic therapy (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist, provided that no systemic treatment is given within 2 weeks prior to RT, concurrent with RT or within a 2-week period post RT.
  • Concurrent palliative RT to other metastatic sites is permissible
  • Life expectancy > 3 months

Exclusion Criteria:

  • Prior thoracic RT
  • Serious medical comorbidities precluding RT
  • Pregnant or lactating women
  • Inability to attend the full course of RT or planned follow-up visits
  • Planned concurrent palliative RT to the stomach and/or liver
  • Congenital abnormalities of the esophagus or severe disorders of the esophagus (e.g. achalasia)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02752126


Locations
Layout table for location information
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Nova Scotia
Atlantic Clinical Cancer Centre
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Grand River Regional Cancer Centre/Grand River Hospital
Kitchener, Ontario, Canada, N2G 1G3
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
Princess Margaret Hospital/ University Health Network
Toronto, Ontario, Canada, M5G 2M9
Canada, ONT
Trillium Health Partners - Credit Valley Hospital
Mississauga, ONT, Canada, L5M 2N1
Canada, Quebec
McGill University Health Centre
Montréal, Quebec, Canada, H3H 2R9
Sponsors and Collaborators
Lawson Health Research Institute
Layout table for additonal information
Responsible Party: Alexander Louie, Radiation Oncologist, Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT02752126    
Other Study ID Numbers: PROACTIVE
First Posted: April 26, 2016    Key Record Dates
Last Update Posted: September 9, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Alexander Louie, Lawson Health Research Institute:
Esophageal sparing
Conventional radiotherapy
Palliative radiation
Central lung tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases